For the year ending 2025-12-31, NPCE had $8,262K increase in cash & cash equivalents over the period. -$11,338K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -21,465 |
| Stock-based compensation expense | 11,089 |
| Depreciation | 238 |
| Amortization of debt discount and issuance costs | 237 |
| Non-cash interest expense | 538 |
| Pik interest incurred but not paid on term loan | 0 |
| Loss on debt extinguishment | -527 |
| Amortization of right-of-use asset | 1,710 |
| Gain on short-term investments | 41 |
| Inventory write-downs | 159 |
| Loss on disposal of property and equipment | -14 |
| Accounts receivable | 1,830 |
| Inventory | 3,673 |
| Prepaid expenses and other assets | -943 |
| Accounts payable | -730 |
| Accrued liabilities | 3,552 |
| Deferred revenue | -414 |
| Operating lease liabilities | -1,860 |
| Net cash used in operating activities | -11,006 |
| Acquisition of property and equipment | 332 |
| Proceeds from sale of short-term investments | 0 |
| Net cash (used in) provided by investing activities | -332 |
| Proceeds from issuance of common stock in follow-on offering, net of underwriting discounts and commissions-Follow On Offering | 69,654 |
| Repurchase of common stock from kck ltd | 49,546 |
| Proceeds from issuance of common stock under employee plans | 1,875 |
| Taxes withheld and paid related to net share settlement of equity awards | 543 |
| Proceeds from at-the-market offering, net of sales commission-At The Market Equity Offering | 232 |
| Proceeds from debt, net of discounts and issuance costs-At The Market Equity Offering | 58,435 |
| Repayment of debt-At The Market Equity Offering | 60,507 |
| Net cash provided by financing activities | 19,600 |
| Net increase (decrease) in cash and cash equivalents | 8,262 |
| Cash, cash equivalents and restricted cash at the beginning of period | 13,552 |
| Cash, cash equivalents and restricted cash at the end of period | 21,814 |
NeuroPace Inc (NPCE)
NeuroPace Inc (NPCE)